A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia

Naveen Pemmaraju, Hagop Kantarjian, Tapan Kadia, Jorge Cortes, Gautam Borthakur, Kate Newberry, Guillermo Garcia-Manero, Farhad Ravandi, Elias Jabbour, Sara Dellasala, Sherry Pierce, Srdan Verstovsek

Research output: Contribution to journalArticle

Abstract

Background Ruxolitinib is a potent and specific JAK1/JAK2 inhibitor recently approved for the treatment of myelofibrosis. Patients and Methods We conducted a single-center phase I/II clinical study testing 3 dose levels (50 mg b.i.d. [n = 4], 100 mg b.i.d. [n = 5], and 200 mg b.i.d. [n = 18]). We enrolled 27 patients older than 14 years with relapsed or refractory acute myeloid leukemia (n = 26) or acute lymphoid leukemia (n = 1). Results The median age was 66 (range, 25-88) years. Thirteen patients were evaluable for dose-limiting toxicities. The most common Grade 3 or 4 nonhematologic event was infection (n = 26 events; most frequently pneumonia; 15 of 26; 58%). One patient with multiple relapses after 7 lines of therapy had a CRp at a ruxolitinib dose of 200 mg b.i.d. Conclusion In this cohort of heavily pretreated patients with relapsed or refractory acute leukemias, ruxolitinib was overall reasonably well tolerated, with 1 patient achieving CRp.

Original languageEnglish (US)
Pages (from-to)171-176
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Volume15
Issue number3
DOIs
StatePublished - Mar 1 2015
Externally publishedYes

Fingerprint

Janus Kinase 1
Janus Kinase 2
Acute Myeloid Leukemia
Primary Myelofibrosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma
INCB018424
Pneumonia
Leukemia
Recurrence
Therapeutics
Infection

Keywords

  • Acute myelogenous leukemia
  • Clinical study
  • JAK2V617 mutation
  • Janus kinase inhibitor
  • Myelofibrosis
  • Ruxolitinib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. / Pemmaraju, Naveen; Kantarjian, Hagop; Kadia, Tapan; Cortes, Jorge; Borthakur, Gautam; Newberry, Kate; Garcia-Manero, Guillermo; Ravandi, Farhad; Jabbour, Elias; Dellasala, Sara; Pierce, Sherry; Verstovsek, Srdan.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, No. 3, 01.03.2015, p. 171-176.

Research output: Contribution to journalArticle

Pemmaraju, N, Kantarjian, H, Kadia, T, Cortes, J, Borthakur, G, Newberry, K, Garcia-Manero, G, Ravandi, F, Jabbour, E, Dellasala, S, Pierce, S & Verstovsek, S 2015, 'A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia', Clinical Lymphoma, Myeloma and Leukemia, vol. 15, no. 3, pp. 171-176. https://doi.org/10.1016/j.clml.2014.08.003
Pemmaraju, Naveen ; Kantarjian, Hagop ; Kadia, Tapan ; Cortes, Jorge ; Borthakur, Gautam ; Newberry, Kate ; Garcia-Manero, Guillermo ; Ravandi, Farhad ; Jabbour, Elias ; Dellasala, Sara ; Pierce, Sherry ; Verstovsek, Srdan. / A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. In: Clinical Lymphoma, Myeloma and Leukemia. 2015 ; Vol. 15, No. 3. pp. 171-176.
@article{6cdb8a314e9145a0a921d1b0b542f104,
title = "A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia",
abstract = "Background Ruxolitinib is a potent and specific JAK1/JAK2 inhibitor recently approved for the treatment of myelofibrosis. Patients and Methods We conducted a single-center phase I/II clinical study testing 3 dose levels (50 mg b.i.d. [n = 4], 100 mg b.i.d. [n = 5], and 200 mg b.i.d. [n = 18]). We enrolled 27 patients older than 14 years with relapsed or refractory acute myeloid leukemia (n = 26) or acute lymphoid leukemia (n = 1). Results The median age was 66 (range, 25-88) years. Thirteen patients were evaluable for dose-limiting toxicities. The most common Grade 3 or 4 nonhematologic event was infection (n = 26 events; most frequently pneumonia; 15 of 26; 58{\%}). One patient with multiple relapses after 7 lines of therapy had a CRp at a ruxolitinib dose of 200 mg b.i.d. Conclusion In this cohort of heavily pretreated patients with relapsed or refractory acute leukemias, ruxolitinib was overall reasonably well tolerated, with 1 patient achieving CRp.",
keywords = "Acute myelogenous leukemia, Clinical study, JAK2V617 mutation, Janus kinase inhibitor, Myelofibrosis, Ruxolitinib",
author = "Naveen Pemmaraju and Hagop Kantarjian and Tapan Kadia and Jorge Cortes and Gautam Borthakur and Kate Newberry and Guillermo Garcia-Manero and Farhad Ravandi and Elias Jabbour and Sara Dellasala and Sherry Pierce and Srdan Verstovsek",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.clml.2014.08.003",
language = "English (US)",
volume = "15",
pages = "171--176",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "3",

}

TY - JOUR

T1 - A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia

AU - Pemmaraju, Naveen

AU - Kantarjian, Hagop

AU - Kadia, Tapan

AU - Cortes, Jorge

AU - Borthakur, Gautam

AU - Newberry, Kate

AU - Garcia-Manero, Guillermo

AU - Ravandi, Farhad

AU - Jabbour, Elias

AU - Dellasala, Sara

AU - Pierce, Sherry

AU - Verstovsek, Srdan

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background Ruxolitinib is a potent and specific JAK1/JAK2 inhibitor recently approved for the treatment of myelofibrosis. Patients and Methods We conducted a single-center phase I/II clinical study testing 3 dose levels (50 mg b.i.d. [n = 4], 100 mg b.i.d. [n = 5], and 200 mg b.i.d. [n = 18]). We enrolled 27 patients older than 14 years with relapsed or refractory acute myeloid leukemia (n = 26) or acute lymphoid leukemia (n = 1). Results The median age was 66 (range, 25-88) years. Thirteen patients were evaluable for dose-limiting toxicities. The most common Grade 3 or 4 nonhematologic event was infection (n = 26 events; most frequently pneumonia; 15 of 26; 58%). One patient with multiple relapses after 7 lines of therapy had a CRp at a ruxolitinib dose of 200 mg b.i.d. Conclusion In this cohort of heavily pretreated patients with relapsed or refractory acute leukemias, ruxolitinib was overall reasonably well tolerated, with 1 patient achieving CRp.

AB - Background Ruxolitinib is a potent and specific JAK1/JAK2 inhibitor recently approved for the treatment of myelofibrosis. Patients and Methods We conducted a single-center phase I/II clinical study testing 3 dose levels (50 mg b.i.d. [n = 4], 100 mg b.i.d. [n = 5], and 200 mg b.i.d. [n = 18]). We enrolled 27 patients older than 14 years with relapsed or refractory acute myeloid leukemia (n = 26) or acute lymphoid leukemia (n = 1). Results The median age was 66 (range, 25-88) years. Thirteen patients were evaluable for dose-limiting toxicities. The most common Grade 3 or 4 nonhematologic event was infection (n = 26 events; most frequently pneumonia; 15 of 26; 58%). One patient with multiple relapses after 7 lines of therapy had a CRp at a ruxolitinib dose of 200 mg b.i.d. Conclusion In this cohort of heavily pretreated patients with relapsed or refractory acute leukemias, ruxolitinib was overall reasonably well tolerated, with 1 patient achieving CRp.

KW - Acute myelogenous leukemia

KW - Clinical study

KW - JAK2V617 mutation

KW - Janus kinase inhibitor

KW - Myelofibrosis

KW - Ruxolitinib

UR - http://www.scopus.com/inward/record.url?scp=84923611231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923611231&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2014.08.003

DO - 10.1016/j.clml.2014.08.003

M3 - Article

C2 - 25441108

AN - SCOPUS:84923611231

VL - 15

SP - 171

EP - 176

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 3

ER -